Investor crosses 5% stake in Jenburkt Pharmaceuticals via small open market buy

Creeping Acquisition Near ThresholdOwnership Changes View source PDF Explain this filing

JENBURPH · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.7%Reaction day

₹925.05

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.2%-0.9% vs market

Pharmaceuticals peers, median of 168sector-0.3%-0.4% vs sector

On the reaction day the stock moved 0.9 pts less than Nifty Microcap 250 and 0.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.7+0.2-0.9-0.3-0.4

Next day

+0.3+0.9-0.6-0.3+0.7

-1.0-0.8-0.2-1.2+0.2

-0.5-0.1-0.5-1.0+0.5

-2.1-1.7-0.4-2.6+0.5

-3.8-4.3+0.5-4.0+0.2

-6.0-7.5+1.5-6.5+0.6

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 168Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Counter Cyclical Investments Pvt Ltd (acting as Portfolio Manager for clients) acquired 326 shares of Jenburkt Pharmaceuticals in the open market on 9 October 2026, raising its stake from 4.99% to 5.01% (220,931 shares). The tiny 0.01% purchase pushed holding past the 5% mark, triggering the SEBI Regulation 29(1) disclosure. The acquirer is not part of the promoter group. Total equity capital of the company is 44,13,300 shares.

Likely market impact

Marginal institutional buy crossing the 5% disclosure trigger; not a promoter deal, limited direct price impact but signals client interest.